| Title |
Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies
|
|---|---|
| Published in |
International Journal of Hematology, December 2013
|
| DOI | 10.1007/s12185-013-1479-5 |
| Pubmed ID | |
| Authors |
Marco L. Davila, Diana C. G. Bouhassira, Jae H. Park, Kevin J. Curran, Eric L. Smith, Hollie J. Pegram, Renier Brentjens |
| Abstract |
The genetic modification of autologous T cells with chimeric antigen receptors (CARs) represents a breakthrough for gene engineering as a cancer therapy for hematologic malignancies. By targeting the CD19 antigen, we have demonstrated robust and rapid anti-leukemia activity in patients with heavily pre-treated and chemotherapy-refractory B cell acute lymphoblastic leukemia (B-ALL). We demonstrated rapid induction of deep molecular remissions in adults, which has been recently confirmed in a case report involving a child with B-ALL. In contrast to the results when treating B-ALL, outcomes have been more modest in patients with chronic lymphocytic leukemia (CLL) or other non-hodgkin's lymphoma (NHL). We review the clinical trial experience targeting B-ALL and CLL and speculate on the possible reasons for the different outcomes and propose potential optimization to CAR T cell therapy when targeting CLL or other indolent NHL. Lastly, we discuss the pre-clinical development and potential for clinical translation for using CAR T cells against multiple myeloma and acute myeloid leukemia. We highlight the potential risks and benefits by targeting these poor outcome hematologic malignancies. |
X Demographics
The data shown below were collected from the profiles of 40 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 14 | 35% |
| Canada | 1 | 3% |
| India | 1 | 3% |
| Spain | 1 | 3% |
| United Kingdom | 1 | 3% |
| Syrian Arab Republic | 1 | 3% |
| Saudi Arabia | 1 | 3% |
| Australia | 1 | 3% |
| Comoros | 1 | 3% |
| Other | 0 | 0% |
| Unknown | 18 | 45% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 22 | 55% |
| Scientists | 7 | 18% |
| Practitioners (doctors, other healthcare professionals) | 7 | 18% |
| Science communicators (journalists, bloggers, editors) | 3 | 8% |
| Unknown | 1 | 3% |
Mendeley readers
The data shown below were compiled from readership statistics for 183 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 1% |
| Netherlands | 1 | <1% |
| Portugal | 1 | <1% |
| Brazil | 1 | <1% |
| Unknown | 178 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 30 | 16% |
| Student > Bachelor | 29 | 16% |
| Researcher | 26 | 14% |
| Student > Master | 24 | 13% |
| Other | 15 | 8% |
| Other | 21 | 11% |
| Unknown | 38 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 54 | 30% |
| Agricultural and Biological Sciences | 32 | 17% |
| Biochemistry, Genetics and Molecular Biology | 31 | 17% |
| Pharmacology, Toxicology and Pharmaceutical Science | 11 | 6% |
| Immunology and Microbiology | 9 | 5% |
| Other | 10 | 5% |
| Unknown | 36 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 36. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 November 2023.
All research outputs
#1,125,289
of 25,345,468 outputs
Outputs from International Journal of Hematology
#10
of 1,490 outputs
Outputs of similar age
#12,040
of 320,755 outputs
Outputs of similar age from International Journal of Hematology
#1
of 12 outputs
Altmetric has tracked 25,345,468 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,490 research outputs from this source. They receive a mean Attention Score of 4.4. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 320,755 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.